Aurrerapen terapeutikoak Parkinson gaixotasunean

1. Teresa Morera Herreras
2. Maialen Duque
3. Ainhoa Sagarduy Crepo
4. Jorge E. Ortega

Exportar

Exportar

×

MLA

modern-language-association

APA

apa

Chicago

chicago-fullnote-bibliography

Harvard

harvard-cite-them-right

Vancouver

vancouver-author-date

---

RIS BibTex

Exportar

×

El documento no se puede exportar porque pertenece a otro portal.

Texto completo

lock_openTexto completo externo

DIALNET GOOGLE SCHOLAR lock_openAcceso abierto editor

Otras publicaciones en: Ekaia: Euskal Herriko Unibertsitateko zientzi eta teknologi aldizkaria

Resumen

Parkinson’s disease (PD) is a neurodegenerative disorder related to age which prevalence is increasing, estimating that the cases will double in the next 40 years. Currently, among drugs available, L-dopa continues being the most effective therapy, but does not stop or slow down the degeneration. Moreover, its efficacy diminishes over time of treatment while mayor side effects appear, as dyskinesia. This review provides an overview of new therapeutic advances to treat PD, including serotonergic and glutamatergic drugs, pharmacokinetic optimizing pharmaceutical preparations or transcranial magnetic stimulation.

Fuente de los datos: Dialnet